BMS-986360 + capecitabine

**BMS-986360 + capecitabine** is an investigational combination therapy being studied for the treatment of advanced solid tumors, including but not limited to breast cancer, colorectal cancer, lung cancer, pancreatic cancer, renal cell carcinoma, sarcoma, and triple-negative breast cancer. BMS-986360 (also known as CC-90001) is a small molecule, orally active, reversible pan-c-Jun N-terminal kinase (JNK) inhibitor. JNKs (including JNK1, JNK2, JNK3; encoded by MAPK8, MAPK9, MAPK10) are serine/threonine kinases involved in cellular stress signaling, proliferation, survival, and immune response modulation. Inhibition of JNK is hypothesized to modulate the tumor microenvironment toward an anti-tumor immune state and directly inhibit tumor cell proliferation. **Capecitabine** is an oral prodrug of fluorouracil (5-FU), a well-established antimetabolite chemotherapy agent that interferes with DNA synthesis in rapidly dividing cells. This combination is under evaluation to enhance antitumor efficacy via both direct cytotoxicity and modulation of immune responses, and is in phase 1 clinical development. The study is sponsored by Bristol Myers Squibb[2][4][5][6][7].